Citations (54)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Misako Matsumoto, Yohei Takeda & Tsukasa Seya. (2020) Targeting Toll-like receptor 3 in dendritic cells for cancer immunotherapy. Expert Opinion on Biological Therapy 20:8, pages 937-946.
Read now
Read now
William S. Bowen, Abhishek K. Svrivastava, Lalit Batra, Hampartsoum Barsoumian & Haval Shirwan. (2018) Current challenges for cancer vaccine adjuvant development. Expert Review of Vaccines 17:3, pages 207-215.
Read now
Read now
Hiromi Takaki, Hiroaki Shime, Misako Matsumoto & Tsukasa Seya. (2017) Tumor cell death by pattern-sensing of exogenous RNA: Tumor cell TLR3 directly induces necroptosis by poly(I:C) in vivo, independent of immune effector-mediated tumor shrinkage. OncoImmunology 6:10.
Read now
Read now
Masahiro Azuma, Yohei Takeda, Hiroko Nakajima, Haruo Sugiyama, Takashi Ebihara, Hiroyuki Oshiumi, Misako Matsumoto & Tsukasa Seya. (2016) Biphasic function of TLR3 adjuvant on tumor and spleen dendritic cells promotes tumor T cell infiltration and regression in a vaccine therapy. OncoImmunology 5:8.
Read now
Read now
Tsukasa Seya, Yohei Takeda & Misako Matsumoto. (2016) Tumor vaccines with dsRNA adjuvant ARNAX induces antigen-specific tumor shrinkage without cytokinemia. OncoImmunology 5:2.
Read now
Read now
Tsukasa Seya, Masahiro Azuma & Misako Matsumoto. (2013) Targeting TLR3 with no RIG-I/MDA5 activation is effective in immunotherapy for cancer. Expert Opinion on Therapeutic Targets 17:5, pages 533-544.
Read now
Read now
Tsukasa Seya, Hiroaki Shime & Misako Matsumoto. (2012) TAMable tumor-associated macrophages in response to innate RNA sensing. OncoImmunology 1:6, pages 1000-1001.
Read now
Read now
Articles from other publishers (47)
Aristitsa Mikhailovna Kostinova, Elena Alexandrovna Latysheva, Nelly Kimovna Akhmatova, Anna Egorovna Vlasenko, Svetlana Anatolyevna Skhodova, Ekaterina Alexandrovna Khromova, Andrey Viktorovich Linok, Arseniy Alexandrovich Poddubikov, Tatyana Vasilievna Latysheva & Mikhail Petrovich Kostinov. (2023) Expression of Toll-like Receptors on the Immune Cells in Patients with Common Variable Immune Deficiency after Different Schemes of Influenza Vaccination. Viruses 15:10, pages 2091.
Crossref
Crossref
Irene Veneziani, Claudia Alicata, Lorenzo Moretta & Enrico Maggi. (2022) The Latest Approach of Immunotherapy with Endosomal TLR Agonists Improving NK Cell Function: An Overview. Biomedicines 11:1, pages 64.
Crossref
Crossref
M. A. Baryshnikova, A. V. Ponomarev, A. A. Rudakova, Z. A. Sokolova, N. V. Golubtsova, P. V. Tsarapaev, G. M. Levagina, E. D. Danilenko & V. S. Kosorukov. (2022) Comparison of Ridostin Pro and Poly(I:C) as adjuvant for a cancer neoantigen peptide vaccine. Russian Journal of Biotherapy 21:3, pages 82-89.
Crossref
Crossref
Chang Liu, Kun Chen, Fei Zhao, Lingling Xuan, Yuting Wang, Chungui Xu, Zhiyuan Wu, Dongmei Wang & Chunfeng Qu. (2022) Occult infection with hepatitis B virus PreS variants synergistically promotes hepatocellular carcinoma development in a high-fat diet context by generating abnormal ceramides. BMC Medicine 20:1.
Crossref
Crossref
Jay Patel, Spandana Maddukuri, Yubin Li, Christina Bax & Victoria P. Werth. (2021) Highly Multiplexed Mass Cytometry Identifies the Immunophenotype in the Skin of Dermatomyositis. Journal of Investigative Dermatology 141:9, pages 2151-2160.
Crossref
Crossref
Asma Komal, Mamoona Noreen & Attalla F. El-Kott. (2021) TLR3 agonists: RGC100, ARNAX, and poly-IC: a comparative review. Immunologic Research 69:4, pages 312-322.
Crossref
Crossref
Julia Koerner, Dennis Horvath, Valerie L. Herrmann, Anna MacKerracher, Bruno Gander, Hideo Yagita, Jacques Rohayem & Marcus Groettrup. (2021) PLGA-particle vaccine carrying TLR3/RIG-I ligand Riboxxim synergizes with immune checkpoint blockade for effective anti-cancer immunotherapy. Nature Communications 12:1.
Crossref
Crossref
Miku Ishizawa, Undrakh Ganbaatar, Atsuhiko Hasegawa, Natsuko Takatsuka, Nobuyo Kondo, Takeru Yoneda, Kuniko Katagiri, Takao Masuda, Atae Utsunomiya & Mari Kannagi. (2021) Short‐term cultured autologous peripheral blood mononuclear cells as a potential immunogen to activate Tax‐specific CTL response in adult T‐cell leukemia patients. Cancer Science 112:3, pages 1161-1172.
Crossref
Crossref
Tianlin Zhou, Jinrong Peng, Ying Hao, Kun Shi, Kai Zhou, Yun Yang, Chengli Yang, Xinlong He, Xinmian Chen & Zhiyong Qian. (2021) The construction of a lymphoma cell-based, DC-targeted vaccine, and its application in lymphoma prevention and cure. Bioactive Materials 6:3, pages 697-711.
Crossref
Crossref
Kristel Kodar, Melanie J McConnell, Jacquie L Harper, Mattie SM Timmer & Bridget L Stocker. (2020) The coadministration of trehalose dibehenate and monosodium urate crystals promotes an antitumor phenotype in human‐derived myeloid cells. Immunology & Cell Biology 98:5, pages 411-422.
Crossref
Crossref
Tsukasa Seya, Yohei Takeda & Misako Matsumoto. (2019) A Toll-like receptor 3 (TLR3) agonist ARNAX for therapeutic immunotherapy. Advanced Drug Delivery Reviews 147, pages 37-43.
Crossref
Crossref
Shafaqat Ali, Ritu Mann-Nüttel, Anja Schulze, Lisa Richter, Judith Alferink & Stefanie Scheu. (2019) Sources of Type I Interferons in Infectious Immunity: Plasmacytoid Dendritic Cells Not Always in the Driver's Seat. Frontiers in Immunology 10.
Crossref
Crossref
Yohei Takeda, Hiromi Takaki, Aya Fukui-Miyazaki, Sumito Yoshida, Misako Matsumoto & Tsukasa Seya. (2018) Vaccine adjuvant ARNAX promotes mucosal IgA production in influenza HA vaccination. Biochemical and Biophysical Research Communications.
Crossref
Crossref
Mikhail Petrovich Kostinov, Nelli Kimovna Akhmatova, Ekaterina Alexandrovna Khromova, Svetlana Anatolyevna Skhodova, Vera Nikolaevna Stolpnikova, Alexander Petrovich Cherdantsev & Anna Egorovna Vlasenko. 2018. Influenza - Therapeutics and Challenges. Influenza - Therapeutics and Challenges.
Eric Lin, Thong CaoSunitha Nagrath & Michael R. King. (2018) Circulating Tumor Cells: Diagnostic and Therapeutic Applications. Annual Review of Biomedical Engineering 20:1, pages 329-352.
Crossref
Crossref
Takashi Akazawa, Toshimitsu Ohashi, Viskam Wijewardana, Kikuya Sugiura & Norimitsu Inoue. (2018) Development of a vaccine based on bacteria‐mimicking tumor cells coated with novel engineered toll‐like receptor 2 ligands. Cancer Science 109:5, pages 1319-1329.
Crossref
Crossref
Sumito Yoshida, Hiroaki Shime, Yohei Takeda, Jin‐Min Nam, Ken Takashima, Misako Matsumoto, Hiroki Shirato, Masanori Kasahara & Tsukasa Seya. (2018) Toll‐like receptor 3 signal augments radiation‐induced tumor growth retardation in a murine model. Cancer Science 109:4, pages 956-965.
Crossref
Crossref
Blake Alan Scott, Mark YarchoanElizabeth M. Jaffee. (2018) Prophylactic Vaccines for Nonviral Cancers. Annual Review of Cancer Biology 2:1, pages 195-211.
Crossref
Crossref
Hyejin Kim, Takashi Kimoto, Satoko Sakai, Etsuhisa Takahashi & Hiroshi Kido. (2018) Adjuvanting influenza hemagglutinin vaccine with a human pulmonary surfactant-mimicking synthetic compound SF-10 induces local and systemic cell-mediated immunity in mice. PLOS ONE 13:1, pages e0191133.
Crossref
Crossref
Misako Matsumoto, Yohei Takeda, Megumi Tatematsu & Tsukasa Seya. (2017) Toll-Like Receptor 3 Signal in Dendritic Cells Benefits Cancer Immunotherapy. Frontiers in Immunology 8.
Crossref
Crossref
Junya Ono, Hiroaki Shime, Hiromi Takaki, Ken Takashima, Kenji Funami, Sumito Yoshida, Yohei Takeda, Misako Matsumoto, Masanori Kasahara & Tsukasa Seya. (2017) The TLR3/TICAM-1 signal constitutively controls spontaneous polyposis through suppression of c-Myc in Apc
Min/+
mice. Journal of Biomedical Science 24:1.
Crossref
Crossref
Yingjie Nie, De Yang, Anna Trivett, Zhen Han, Haiyun Xin, Xin Chen & Joost J. Oppenheim. (2017) Development of a Curative Therapeutic Vaccine (TheraVac) for the Treatment of Large Established Tumors. Scientific Reports 7:1.
Crossref
Crossref
Kenji Funami, Misako Matsumoto, Hiroyuki Oshiumi, Fuyuhiko Inagaki & Tsukasa Seya. (2017) Functional interfaces between TICAM-2/TRAM and TICAM-1/TRIF in TLR4 signaling. Biochemical Society Transactions 45:4, pages 929-935.
Crossref
Crossref
Yohei Takeda, Keisuke Kataoka, Junya Yamagishi, Seishi Ogawa, Tsukasa Seya & Misako Matsumoto. (2017) A TLR3-Specific Adjuvant Relieves Innate Resistance to PD-L1 Blockade without Cytokine Toxicity in Tumor Vaccine Immunotherapy. Cell Reports 19:9, pages 1874-1887.
Crossref
Crossref
Hiroaki Shime, Misako Matsumoto & Tsukasa Seya. (2016) Double-stranded RNA promotes CTL-independent tumor cytolysis mediated by CD11b+Ly6G+ intratumor myeloid cells through the TICAM-1 signaling pathway. Cell Death & Differentiation 24:3, pages 385-396.
Crossref
Crossref
Yohei Takeda, Masahiro Azuma, Misako Matsumoto & Tsukasa Seya. (2016) Tumoricidal efficacy coincides with CD11c up-regulation in antigen-specific CD8+ T cells during vaccine immunotherapy. Journal of Experimental & Clinical Cancer Research 35:1.
Crossref
Crossref
Tsukasa Seya, Hiroaki Shime, Yohei Takeda, Megumi Tatematsu, Ken Takashima & Misako Matsumoto. (2015) Adjuvant for vaccine immunotherapy of cancer – focusing on Toll‐like receptor 2 and 3 agonists for safely enhancing antitumor immunity. Cancer Science 106:12, pages 1659-1668.
Crossref
Crossref
Masato Nakai, Hiroyuki Oshiumi, Kenji Funami, Masaaki Okamoto, Misako Matsumoto, Tsukasa Seya & Naoya Sakamoto. (2015) Interferon (IFN) and Cellular Immune Response Evoked in RNA-Pattern Sensing During Infection with Hepatitis C Virus (HCV). Sensors 15:10, pages 27160-27173.
Crossref
Crossref
Bangqing Yuan, Hanchao Shen, Tonggang Su, Li Lin, Ting Chen & Zhao Yang. (2015) A novel nanoparticle containing neuritin peptide with grp170 induces a CTL response to inhibit tumor growth. Journal of Neuro-Oncology 125:1, pages 23-32.
Crossref
Crossref
Tsutomu Tanaka, Toshimitsu Kajiwara, Goro Kutomi, Takehiro Kurotaki, Keita Saito, Takayuki Kanaseki, Tomohide Tsukahara, Yoshihiko Hirohashi, Toshihiko Torigoe, Koichi Hirata, Yoshiharu Okamoto, Noriyuki Sato & Yasuaki Tamura. (2015) CpG-A stimulates Hsp72 secretion from plasmacytoid dendritic cells, facilitating cross-presentation. Immunology Letters 167:1, pages 34-40.
Crossref
Crossref
Ryo Takemura, Hiromi Takaki, Seiji Okada, Hiroaki Shime, Takashi Akazawa, Hiroyuki Oshiumi, Misako Matsumoto, Takanori Teshima & Tsukasa Seya. (2015)
PolyI:C–Induced, TLR3/RIP3-Dependent Necroptosis Backs Up Immune Effector–Mediated Tumor Elimination
In Vivo
. Cancer Immunology Research 3:8, pages 902-914.
Crossref
Crossref
Andrew K. Hastings, John J. Erickson, Jennifer E. Schuster, Kelli L. Boyd, Sharon J. Tollefson, Monika Johnson, Pavlo Gilchuk, Sebastian Joyce & John V. Williams. (2015) Role of Type I Interferon Signaling in Human Metapneumovirus Pathogenesis and Control of Viral Replication. Journal of Virology 89:8, pages 4405-4420.
Crossref
Crossref
Misako Matsumoto, Megumi Tatematsu, Fumiko Nishikawa, Masahiro Azuma, Noriko Ishii, Akiko Morii-Sakai, Hiroaki Shime & Tsukasa Seya. (2015) Defined TLR3-specific adjuvant that induces NK and CTL activation without significant cytokine production in vivo. Nature Communications 6:1.
Crossref
Crossref
Jun Kasamatsu, Shojiro Takahashi, Masahiro Azuma, Misako Matsumoto, Akiko Morii-Sakai, Masahiro Imamura, Takanori Teshima, Akari Takahashi, Yoshihiko Hirohashi, Toshihiko Torigoe, Noriyuki Sato & Tsukasa Seya. (2015) PolyI:C and mouse survivin artificially embedding human 2B peptide induce a CD4+ T cell response to autologous survivin in HLA-A*2402 transgenic mice. Immunobiology 220:1, pages 74-82.
Crossref
Crossref
Hiroaki Shime, Misako Matsumoto & Tsukasa Seya. 2015. Inflammation and Immunity in Cancer. Inflammation and Immunity in Cancer
25
47
.
Misako Matsumoto, Masahiro Azuma & Tsukasa Seya. 2015. Inflammation and Immunity in Cancer. Inflammation and Immunity in Cancer
229
241
.
Laure Ysebrant de Lendonck, Valerie Martinet & Stanislas Goriely. (2014) Interferon regulatory factor 3 in adaptive immune responses. Cellular and Molecular Life Sciences 71:20, pages 3873-3883.
Crossref
Crossref
David G. Hancock, Elena Shklovskaya, Thomas V. Guy, Reza Falsafi, Chris D. Fjell, William Ritchie, Robert E. W. Hancock & Barbara Fazekas de St Groth. (2014) A Systems Biology Approach to the Analysis of Subset-Specific Responses to Lipopolysaccharide in Dendritic Cells. PLoS ONE 9:6, pages e100613.
Crossref
Crossref
Megumi Tatematsu, Tsukasa Seya & Misako Matsumoto. (2014) Beyond dsRNA: Toll-like receptor 3 signalling in RNA-induced immune responses. Biochemical Journal 458:2, pages 195-201.
Crossref
Crossref
Hiroaki Shime, Ayako Kojima, Akira Maruyama, Yusuke Saito, Hiroyuki Oshiumi, Misako Matsumoto & Tsukasa Seya. (2014) Myeloid-Derived Suppressor Cells Confer Tumor-Suppressive Functions on Natural Killer Cells via Polyinosinic:Polycytidylic Acid Treatment in Mouse Tumor Models. Journal of Innate Immunity 6:3, pages 293-305.
Crossref
Crossref
Susan N. Thomas, Efthymia Vokali, Amanda W. Lund, Jeffrey A. Hubbell & Melody A. Swartz. (2014) Targeting the tumor-draining lymph node with adjuvanted nanoparticles reshapes the anti-tumor immune response. Biomaterials 35:2, pages 814-824.
Crossref
Crossref
Misako Matsumoto, Kenji Funami, Megumi Tatematsu, Masahiro Azuma & Tsukasa Seya. 2014. Endosome Signaling Part B. Endosome Signaling Part B
149
165
.
Toshimitsu Ohashi, Takashi Akazawa, Mitsuhiro Aoki, Bunya Kuze, Keisuke Mizuta, Yatsuji Ito & Norimitsu Inoue. (2013) Dichloroacetate improves immune dysfunction caused by tumor-secreted lactic acid and increases antitumor immunoreactivity. International Journal of Cancer 133:5, pages 1107-1118.
Crossref
Crossref
Hiroyuki Oshiumi, Kenji Funami, Hussein H. Aly, Misako Matsumoto & Tsukasa Seya. (2013) Multi-Step Regulation of Interferon Induction by Hepatitis C Virus. Archivum Immunologiae et Therapiae Experimentalis 61:2, pages 127-138.
Crossref
Crossref
Tsukasa SEYA, Hiroyuki OSHIUMI & Misako MATSUMOTO. (2013) Immunobiological response against RNA virus infection. Uirusu 63:2, pages 135-142.
Crossref
Crossref
Misako Matsumoto, Kenji Funami, Hiroyuki Oshiumi & Tsukasa Seya. 2013. Oligomerization in Health and Disease. Oligomerization in Health and Disease
487
510
.
Stephanie K. Watkins & Arthur A. Hurwitz. 2013. The Tumor Immunoenvironment. The Tumor Immunoenvironment
431
455
.